BioMS Medical announces first quarter 20...(01 trial may choose to receive dirucotid...)

(MBP8298) on an un-blinded basis. To date, approximately 95% of

patients enrolled in MAESTRO-01 have proceeded to MAESTRO-02.

- MAESTRO-03: A U.S. pivotal phase III trial evaluating dirucotide

(MBP8298) for the treatment of SPMS. Enrollment for the randomized,

double-blind study was initiated in June, 2007 and to date there have

been in excess of 375 patients enrolled. The trial will include

approximately 510 patients at approximately 68 sites across the U.S.

To date, the DSMB has conducted two reviews of the data from this

trial and has recommended it continue. The trial is expected to

complete enrollment in mid-2008.

- MINDSET-01: A phase II clinical trial evaluating dirucotide (MBP8298)

for the treatment of relapsing-remitting MS (RRMS). The randomized,

double-blind study has completed recruitment with 218 patients

enrolled at 24 trial sites in 6 countries across Europe. The DSMB has

completed three safety analyses to date and recommended that the

trial continue as per the protocol. Completion of the trial is

expected at the end of 2008 with results anticipated in the first

half of 2009.

Licensing and Development Agreement

On December 17, 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298). Under the terms of the agreement, Lilly and BioMS will collaborate on the development of dirucotide (MBP8298) and will also share in certain development costs with Lilly being responsible for future research and development, manufacturing and marketing activities. The transaction closed on January 25, 2008 with the receipt of an upfront payment of US$87 million. BioMS has the potential to receive additional development and sales milestones of up to US $410
'/>"/>